Drug Profile
Research programme: PACE 4 inhibitors - BiolineRx/Institut de pharmacologie de Sherbrooke
Alternative Names: EDP-31Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Institut de pharmacologie de Sherbrooke
- Developer BioLineRx; Institut de pharmacologie de Sherbrooke
- Class
- Mechanism of Action PCSK6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada
- 27 Sep 2013 Early research is ongoing in Israel
- 18 Dec 2012 Preclinical trials in Cancer in Canada (unspecified route)